Health Canada approves OzempicĀ® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
OzempicĀ® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…